Funding for this research was provided by:
Sanofi
Article History
Received: 3 August 2023
Accepted: 4 October 2023
First Online: 23 November 2023
Change Date: 16 February 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s40121-024-00928-z
Declarations
:
: Stefania Maggi received research grants and personal fees as an advisory board member and/or speaker from GSK, Pfizer, Sanofi, Takeda, Viatris, Janssen, Novavax, and Moderna. Annemarijn de Boer has been an invited speaker at an industry sponsored symposium. The symposium was sponsored by Sanofi. Honoraria was paid to the institution. Melissa Andrew reports prior honoraria for advisory activities from Pfizer, Sanofi and Seqirus, and grant funding from GSK, Sanofi, Pfizer, Merck, Public Health Agency of Canada, Canadian Frailty Network, Fondation de France, and Canadian Institutes of Health Research. She is a member of Canada’s National Advisory Committee on Immunization.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.